WASHINGTON, April 21, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential claims on behalf of investors who purchased securities of Zenas BioPharma, Inc. (NASDAQ:ZBIO) pursuant and/or traceable to the Company's September 2024 initial public offering ("IPO"). Investors who suffered significant losses are encouraged to contact the firm. [Click here for information about joining the class action] CASE OVERVIEW: Zenas BioPharma, a clinical-stage biopharmaceutical company, held ...

Core Viewpoint - A class action lawsuit has been filed against Zenas BioPharma, Inc. for violations of federal securities laws related to misleading statements made during its IPO [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by the Schall Law Firm, which specializes in shareholder rights litigation [1][5]. - Investors who purchased Zenas securities during its IPO on September 13, 2024, are encouraged to contact the firm before June 16, 2025, to discuss their rights [2][3]. Group 2: Allegations Against Zenas - The complaint alleges that Zenas made false and misleading statements regarding the sustainability of its operations based on existing cash and expected IPO proceeds [4]. - It is claimed that these misleading statements caused investors to suffer damages once the truth about the company's financial situation was revealed [4].

SAN DIEGO, April 21, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit.  Captioned Buathongsri v. Zen ...

NEW YORK, April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=143839&from=4CLASS PERIOD: This lawsu ...

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Buathongsri v. Zenas BioPharma, Inc., allows purchasers of Zenas BioPharma securities from its IPO on September 13, 2024, to seek lead plaintiff status by June 16, 2025 [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, which is 48.7% lower than the IPO price of $17.00 per share [4]. Group 2: Company Background - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies [2]. - The company sold over 13 million shares during its IPO at a price of $17.00 per share [2]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Zenas BioPharma, Inc. securities related to its September 2024 IPO, alleging misleading statements in the Registration Statement [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false public statements [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion by June 16, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Zenas BioPharma, Inc. securities related to its September 2024 IPO, alleging misleading statements in the Registration Statement [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false public statements [5]. - Investors who purchased Zenas BioPharma securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by June 16, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - A class action has been filed against Zenas BioPharma, Inc. for allegedly misleading investors during its IPO by overstating the duration it could fund its operations with existing cash and expected net proceeds from the IPO [1][2]. Group 1: Allegations and Financial Impact - The complaint states that Zenas BioPharma failed to disclose that it could only fund its operations for twelve months instead of the twenty-four months previously claimed in the Registration Statement [2]. - Following the disclosure of these material adverse facts, Zenas BioPharma's share price has significantly declined, closing at $8.72 on April 15, 2025, which is 48.7% lower than its IPO price [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by June 16, 2025, and they do not need to participate in the case to be eligible for recovery [3]. - The class action allows shareholders to act collectively against the alleged wrongdoing of Zenas BioPharma [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless there is a recovery [4].

SAN DIEGO, April 18, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit.  Captioned Bu ...

Core Viewpoint - A securities class action lawsuit has been filed against Zenas BioPharma, alleging that the company made false and misleading statements regarding its financial stability during its IPO [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Zenas BioPharma securities during the IPO on or around September 13, 2024 [1]. - The complaint claims that the Registration Statement contained misleading information about the company's ability to fund its operations [2]. Group 2: Financial Misrepresentation - It is alleged that Zenas BioPharma overstated the duration it could fund its operations using existing cash and expected IPO proceeds [2]. - The company's quarterly report filed on November 12, 2024, indicated it could fund operations for only twelve months, contrary to the twenty-four months stated in the Registration Statement [3]. Group 3: Impact on Share Price - Following the disclosure of omitted material facts, Zenas BioPharma's share price has significantly declined, closing at $8.72 on April 15, 2025, which is 48.7% below the IPO price [3].